Johnson & Johnson (JNJ)

These companies generate resilient revenues, which help make their stocks less volatile during market downturns.

The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.

These funds can help you weather any storm that might be on the way.

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.

This exchange-traded fund consistently outperforms the S&P 500 thanks to its concentrated portfolio of growth stocks.

International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO.

Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.

Johnson & Johnson beat earnings this morning. Then its stock price dropped.

Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.

Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.

Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in its Innovative Medicine business offset slower-than-expected performance in parts of MedTech. The company raised its full-year sales outlook and said it re

Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.

These companies have a long history of dividend growth.

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.